NCKAP1L and triple-A syndrome: In conclusion, our data indicate that lncRNA PVT1 is involved in AAA progression by sequestering miR-3127-5p and enhancing the expression of its target, NCKAP1L, indicating that the PVT1/miR-3127-5p/NCKAP1L axis could be an ideal drug target for AAA prevention.